Healthequity (NASDAQ:HQY) Releases Quarterly Earnings Results, Beats Expectations By $0.27 EPS

Healthequity (NASDAQ:HQY) issued its quarterly earnings data on Tuesday. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.15 by $0.27, MarketWatch Earnings reports. The firm had revenue of $176.00 million during the quarter, compared to the consensus estimate of $171.11 million. Healthequity had a positive return on equity of 9.18% and a negative net margin of 2.74%. The company’s quarterly revenue was up 102.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 earnings per share. Healthequity updated its FY 2021
After-Hours guidance to 1.48-1.58 EPS and its FY21 guidance to $1.48-$1.58 EPS.

Shares of NASDAQ HQY opened at $55.19 on Friday. The stock has a fifty day simple moving average of $55.56 and a two-hundred day simple moving average of $56.41. Healthequity has a 1-year low of $34.40 and a 1-year high of $88.78. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of -204.40, a price-to-earnings-growth ratio of 4.32 and a beta of 1.40. The company has a current ratio of 2.11, a quick ratio of 2.11 and a debt-to-equity ratio of 1.12.

Several brokerages have recently commented on HQY. Zacks Investment Research downgraded Healthequity from a “strong-buy” rating to a “sell” rating and set a $64.00 price objective for the company. in a research note on Tuesday, June 16th. Barrington Research increased their price target on Healthequity from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday. Deutsche Bank increased their price target on Healthequity from $57.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald decreased their price target on Healthequity from $80.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Finally, Raymond James reaffirmed a “buy” rating on shares of Healthequity in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $63.75.

In other news, VP Ashley Dreier sold 16,250 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $60.00, for a total value of $975,000.00. Following the completion of the transaction, the vice president now directly owns 58,694 shares of the company’s stock, valued at $3,521,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Article: How does equity income fit into an investing strategy?

Earnings History for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.